Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Investor Presentation (September 2017)

19 slides from Avadel Pharmaceuticals's investor presentation, Sep 6, 2017

  1. Slide 1: Noctiva Investor Presentation

    Noctiva™ Invest wAva d a | Avadel Pharmaceuticals plc POWER OF MEDICINE, REINVENTED September 6 September6, 2017

  2. Slide 2: Safe Harbor

    Safe Harbor Yr Avadel Safe Harbor: This investor slide presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 41933 and Section 216 of the Securities Exchange Act of 1934. The words “will” “may,” “believe,” “expect,” “anticipate,” “estimate,” “

  3. Slide 3: Our Transition to Branded Specialty Pharma

    Our Transition to Branded Specialty Pharma N Avadel specialty patient populations. 2013 - 2014 * Acquired Eclat FDA approved * FDA approved Akovaz® * Reincorporated in Pharmaceuticals is 4 « Bloxiverz® + Acquired FSC Pediatrics Ireland pipeline ot Unapproye + Vazculep® iti + Noctiva™ Marketed Drugs

  4. Slide 4: First & Only FDA-Approved Treatment for nocturia due to nocturnal polyuria

    — First & Only FDA-Approved Treatment for nocturia due to nocturnal polyuria ~ An estimated 40 million Americans suffer from nocturia* - Less than 10% patients are being treated*

  5. Slide 5: Noctiva Rationale

    Noctiva™ Rationale : Avadel Noctiva is a unique, patent-protected specialty product that diversifies our revenue streams, reduces dependence on branded generics and will deliver value to Avadel investors, employees, health care professionals and most importantly - patients. Septernber6, 2017 &

  6. Slide 6: Nocturia: Issues & Opportunities

    u Vv Nocturia: Issues & Opportunities \ Avadel Septernber6, 2017 6

  7. Slide 7: Nocturia: Prevalence in Men & Women

    Prevalence (%) Nocturia: Prevalencein Men & Women \yAvadel Men Women ‘00 wo 80: Saw 7 pe = ra 8 2 5 g 2 & ° 20 ra 60 ny 100 e * oo * ‘0 Age (years) Age (years) Bosch LHP and \Weiss JP: The prevalence and causes of nocturia. J Urol 184: Aug 2010, September6, 2017 — 21 voidinight — 22 voidsinght (or>1

  8. Slide 8: Nocturia: Nocturnal Polyuria in Majority of Patients

    Nocturia: Nocturnal Polyuria in Majority of Pat Avadel Europe? Japan? USA$ n=845 n=41* n=934 HE xe = Without ne Septernber6, 2017 ®

  9. Slide 9: Nocturia: Quality of Life

    Level Value Nocturia: Quality of Life —— ++ Nonocturia -® 1 Episodeinight —t- 2Episodesinight ~®- 23 Episodesinight Worsening > <— Worsening fortrend) 196. 15D instrument: Sintonen. Ann Myeean ssa:

  10. Slide 10: Nocturia: Severity & Bothersomeness

    Nocturia: Severity & Bothersomeness —— Bother None Small Moderate Major Nocturia episodes % % % % One S272 AL. Two Three 174 Fouror more T1.3 7.0 (N=3,474) Baseline number of nocturic episodes was 3.1 Tikkinen et al, Sur Uro/2010,57: 488-496. September! 6.2017

  11. Slide 11: Nocturia: Falls in Elderly Patients

    Nocturia: Falls in Elderly Patients —— * 5,872 community-dwelling US men ag * Primary outcome: 1-year cumulative inciden + Nocturia was among the LUTS most strongly Yr Avadel of falls with moderate/severe vs mild LUTS at baseline ssociated with falls 2-3 Episodes/Night 4-5 Episodes/Night % % R (95%

  12. Slide 12: Nocturia: Association with Adverse Outcomes

    Nocturia: Association with Adverse Outcomes Age Group Unadjusted Outcome HR (95% Cl) \yAvadel Adjusted* HR (95% Cl) CHD Diabetes mellitus 5, 2.11) Hypertension Death 1.06 (0.61, 1.85} 1.05 (0.77, 1.43) 1.36 (0.87, 2.12) 1.31 (0.73, 2.35} “adjusted for baseline age, Bil, use of alpha blocker alpha bl

  13. Slide 13: Nocturia: Mortality

    Nocturia: Mortality Yr Avadel Men Women Survival Probal y Survival Probal y 54 Necturia <2 —— Nocturia 2+ —— Noeturia <2 =9—— Nocturia 2+ 0 12 24 36 48 60 72 84 96 108 120 132 144 0 12 24 36 48 60 72 84 96 108 120 132 144 Months Months 22 voids/night associated with worse survival in population-base

  14. Slide 14: Nocturia: Current Therapy

    Avadel Nocturia: Current Therapy Behavioral modification has not shown durable efficacy in clinical practice Drugs for OAB & BPH have marginal efficacy d for almost 40 years inf | Desmopressin has been use allage groups inclinical prac Noctiva™ is an improved dosage formulationWwith sustained effica

  15. Slide 15: Noctiva: Development

    Noctiva: Development YrAvadel * Noctiva: a synthetic analogue of antidiuretic hormone, vasopressin. Historically, unable to reliably control duration of action, resulting in cases of hyponatremia * Noctiva’s low-dose of desmopressin (7x— 27x lower than existing forms) addresses historical issues — y

  16. Slide 16: Noctiva: Clinical Development

    Noctiva: Clinical Development Yr Avadel * Over 2,300 patients evaluated in clinical efficacystudies * Tworandomized pivotal trials * Statistical efficacy in terms of nocturic episodes & perce greater reduction in nocturicgepisodes _ * Average reduction of nocturic les in responders was 2.1 y * Twolo

  17. Slide 17: Noctiva Launch: 4Q17 & 1H18

    a Vv Noctiva Launch: 4Q17 & 1H18 y Avadel Prepare the market for Noctiva ite educational outreach ograms targeti ealth care profe: d patients -in-class commercial organization ket access and Medical Science Liaison (MSL) teams ealth care profe rocturia patients jective primary care physicians a Sept

  18. Slide 18: Sizing the Market

    Sizing the Market Yr Avadel — Prevalence: ~40 million U.S. patients with nocturia Diagnosed: Independent research & claims data estimate 3 million diagnosed & treated Growing Population: Datashows treated nocturia patients has grown 15% in last 3 years Course of Treatment: Most prescribed drugs to t

  19. Slide 19: Financial Impact

    Financial Impact Yr Avadel Summary Terms: imercial launch, or by June 30, 2018 $1.58 1 of annual net sale million at on net sales between $50 one payments * Tiered mid-double digit royalty ra based ona thres| SG&A Investment * Industry standard launch investment to commercialize Noctiva and build in

Avadel Pharmaceuticals — Investor Presentation (September 2017) on 6ix